2-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic acid | 1017573-16-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic acid
• 英文别名: 2-(Tert-butyldimethylsilyloxy)-3-(tert-butyldisulfanyl)propionic acid；2-[tert-butyl(dimethyl)silyl]oxy-3-(tert-butyldisulfanyl)propanoic acid
• CAS: 1017573-16-8
• 化学式: C₁₃H₂₈O₃S₂Si
• 分子量: 324.581
• InChiKey: TYWBKXQHTCMQAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.64
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic acid 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 生成 S-(p-tolyl) 2-benzamidoethanethioate
  参考文献：
  名称：

  Fmoc-SPPS化学兼容的方法可生成（糖）肽芳基硫酯

  摘要：

  描述了一种新的方法，用于一般的基于Fmoc的（糖）肽芳基硫酯固相合成。通过标准的基于Fmoc的链延长获得的肽烷基氧代酯经历O到S酰基转移，然后与大量过量的芳基硫醇进行烷基硫酯交换，得到相应的肽芳基硫酯。新开发的方法由于与标准Fmoc-SPPS条件兼容，因此可用于化学合成翻译后修饰的蛋白质。另外，肽芳基硫酯是通过动力学控制的收敛策略化学合成蛋白质的重要​​中间体。

  DOI：

  10.1016/j.tetlet.2011.03.064
• 作为产物：
  描述：

  2-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionaldehyde 在 sodium chlorite 、 2-甲基-2-丁烯 、 sodium phosphate buffer 作用下， 以 水 、 叔丁醇 为溶剂， 反应 2.0h， 以66%的产率得到2-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic acid
  参考文献：
  名称：

  Cyclic Peptide Inhibitors of Staphylococcal Virulence Prepared by Fmoc-Based Thiolactone Peptide Synthesis

  摘要：

  Virulence factor production in Staphylococcus aureus is largely under the control of the accessory gene regulator (ago quorum sensing system. There are four agr groups, all of which exhibit bacterial interference: each agr type synthesizes a cyclic autoinducing peptide (AIP) with a distinct sequence that activates its cognate AgrC receptor and inhibits activation of others. To better understand inhibitory AIP-AgrC interactions, we aimed to identify the minimal molecular determinants required to inhibit both non-cognate and cognate receptors. This minimization of the AIP pharmacophore also may have therapeutic relevance as the use of native AIPs to block virulence of non-cognate agr strains can prevent the establishment of an infection in vivo. We synthesized and evaluated the inhibitory activities of 10 AIP derivatives based on a truncated AIP analogue that inhibits all four agr types. To carry out the rapid, parallel synthesis of these peptides, we employed a new linker for Fmoc-based thioester peptide synthesis. Our results identify key structural elements that are necessary for AgrC inhibition and reveal key differences between non-cognate and cognate inhibitory requirements.

  DOI：

  10.1021/ja711126e

文献信息

• PEPTIDE-COMPOUND CYCLIZATION METHOD
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20150080549A1

  公开（公告）日：2015-03-19

  An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.

  本发明的目的是提供一种发现对于难以处理的靶点有效的药物的方法，这些药物通常很难被发现。本发明涉及新型的环化肽化合物的方法，以及包含这些化合物的新型肽库，以实现上述目的。
• Peptide-compound cyclization method
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US09409952B2

  公开（公告）日：2016-08-09

  An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.

  本发明的目的是提供发现对于难以发现的药物目标有效的药物的方法，这些药物目标通常很难被发现。本发明涉及新型的循环肽化合物的方法，以及包含这些化合物的新型肽库，以达到上述目的。